Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Nandrolone

Plain-language summaryIntrigue 52 / 100

Nandrolone (19-nortestosterone) is the parent of an entire class of anabolic steroids defined by the missing 19-carbon. That single deletion does two useful things: it reduces aromatization to estrogen and it prevents 5-alpha-reduction from making a more potent metabolite. Instead, 5-alpha-reduction in skin and other tissues yields dihydronandrolone, which has lower AR affinity than the parent, so androgenic side effects are blunted. The decanoate ester (Deca-Durabolin) gives a 14-day half-life IM; phenylpropionate is faster (3 to 4 days). Approved for anemia of kidney disease and historically for osteoporosis. Schedule III. Heavy non-medical use in bodybuilding for lean mass and (anecdotally) joint support. Sexual dysfunction with prolonged use is attributed to progestogenic metabolites. Canonical 19-nor AAS. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Canonical 19-nor AAS with real reference probe value but no research frontier left to explore

Look, the nandrolone story is genuinely elegant in places, just not in places that matter for a 2025 research agenda. First synthesized in the late 1950s, esterified into Deca-Durabolin by the early 1960s, approved for anemia of chronic kidney disease and historically for osteoporosis. The pharmacology has a neat mechanistic inversion at its core: 5-alpha-reduction of nandrolone produces dihydronandrolone, which carries lower AR affinity than the parent compound. Thats the opposite of the testosterone-to-DHT relationship. The result is tissue-selective anabolism, reduced androgenic expression in tissues dominated by 5-alpha-reductase activity, and a dissociation profile that made 19-nortestosterone derivatives attractive for clinical development in the first place.

But elegant and worked-out-decades-ago are the same thing here. The mechanistic picture is in every AAS pharmacology review going back to the 1970s. The approved-drug status gives nandrolone genuinely solid translational signal, multiple regulatory approvals, and a pharmacokinetic profile that’s been characterized across ester formulations (decanoate at roughly a 14-day half-life, phenylpropionate at 3 to 4 days). That’s a meaningful advantage when you need rigorous comparators or a well-characterized 19-nor AAS in an experimental design. It’s just not a signal pointing at anything new.

The progestogenic activity angle is the most underexplored piece of the puzzle. The so-called deca dick phenomenon, attributed to progestogenic metabolites suppressing the HPG axis and competing at androgen-sensitive circuits in sexual function, is a legitimate research question that hasn’t been fully characterized in clean mechanistic terms. If your program is studying the intersection of progestogenic and androgenic signaling in reproductive neuroendocrinology, nandrolone is the reference compound. There’s no substitute as a canonical 19-nor probe in that specific context.

Outside that niche, we think the bench case for nandrolone as a primary investigation target is weak. The active research community working on tissue-selective anabolism has largely migrated toward SARMs with better selectivity windows and cleaner receptor profiles. The GLP-1 and peptide fields have absorbed the metabolic-anabolic interest. Nandrolone is competing against a much richer pharmacological toolkit and losing on novelty at every turn.

What keeps it off the bottom of the library is exactly that reference utility. Approved drug, well-characterized PK, canonical class membership, real translational signal. If you need a 19-nor AAS in your experiment, this is the compound. Honestly, thats a real but narrow claim, and the score reflects it.

Novelty

18

Mechanism promise

40

In-category differentiation

40

Evidence quality

65

Translational signal

68

Research bench value

55

Rationale Schedule III cap (75) does not bind since the weighted score lands at 45 on its own merits. Nandrolone scores well on evidence and translational signal because it is an approved drug with decades of clinical data, but novelty is near-floor and the mechanism has been fully characterized for 40-plus years; the residual value is as a canonical reference compound for 19-nor AR pharmacology, not as a primary investigation target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

19-nortestosterone (parent of nandrolone class)

19-nortestosterone; the parent compound of the nandrolone class of AAS; the decanoate ester is approved for anemia and osteoporosis.

Abstract

Nandrolone (17-beta-hydroxyestr-4-en-3-one; CAS 434-22-0; molecular formula C18H26O2; molecular weight 274.40) is the parent compound of the 19-nortestosterone (nandrolone) class of AAS; the 19-nor modification reduces aromatization to estrogen and prevents 5-alpha-reduction to a more potent metabolite. The compound itself binds AR with affinity approximately 5-fold higher than testosterone but with reduced effects in some tissues (5-alpha-reduction by 5-AR produces dihydronandrolone, which has lower AR affinity than nandrolone, in contrast to testosterone-DHT relationship; the result is reduced androgenic side effects). The decanoate ester (Deca-Durabolin) provides a 14-day half-life for IM administration; the phenylpropionate ester provides a shorter (3 to 4 day) half-life. Approved for anemia of chronic kidney disease and (historically) osteoporosis. Schedule III. Widely used in non-medical bodybuilding for lean mass gains and (anecdotally) joint support. The “deca dick” sexual dysfunction is attributed to the progestogenic activity of nandrolone metabolites. Used as the canonical 19-nor AAS in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-393Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
GHRP-6

Plain-language summaryIntrigue 58 / 100

GHRP-6 is the original growth hormone releasing peptide and a strong appetite stimulant (because it activates the ghrelin receptor that controls hunger). It produces robust growth hormone release but with the most pronounced cortisol and prolactin elevation among the GHRPs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

First-generation GHRP largely superseded by cleaner alternatives, appetite signal is interesting but not enough

Look, GHRP-6 has a story, but its best chapters were written in the 1990s. It’s a first-generation hexapeptide, one of the original compounds that validated the ghrelin receptor as a viable target for GH secretagogues, and for that it deserves some historical respect. But history isn’t a research rationale.

The mechanism is exactly what you’d expect from something this old: GHSR1a agonism, pulsatile GH release, appetite stimulation through the ghrelin pathway. Solid, well-understood, extensively mapped. The problem is it also drags cortisol and prolactin up in a way that the later-generation GHRPs largely avoid. Ipamorelin came along specifically to solve that problem. Researchers moved on. The cortisol/prolactin elevation isn’t just a safety nuisance in animal models, it complicates any experiment where you’re trying to isolate GH-axis effects. That’s a real methodological liability.

Differentiation is where GHRP-6 genuinely suffers. We think of it mostly as a less clean GHRP-2 or a more side-effect-prone ipamorelin. There’s almost no scenario where it’s the first choice over those two unless you’re specifically studying appetite modulation via ghrelin, which is the one corner where GHRP-6 has a distinctive profile. The appetite stimulation is pronounced and reproducible, and if thats the actual research question, it becomes a relevant tool. Cachexia or sarcopenia models where caloric intake is the outcome variable, for instance. But that is a narrow carve-out, not a broad program.

Evidence quality is moderate. Decades of multi-lab preclinical data exist, and there’s some human work from the 1990s and early 2000s on GH secretion dynamics. But clinical development stalled out, and theres essentially no modern RCT infrastructure behind it. The human translational story is capped by that abandoned trajectory. We’re not looking at a compound with fresh phase 2 data or a revived indication pipeline. What we’re looking at is a reference compound for ghrelin receptor agonism that has been functionally replaced in most experimental designs.

The bench value survives in one specific context: if you’re running a comparative GHRP study and need a first-generation reference point, or if appetite/orexigenic signaling is central to your model, GHRP-6 earns its spot. Outside that, we’d suggest the investigator ask whether ipamorelin or GHRP-2 actually answers their question better before reaching for this one. Most of the time, the answer is yes. That’s the honest position here: not a bad compound, just not the right compound for most research programs that have access to better options.

Novelty

22

Mechanism promise

35

In-category differentiation

22

Evidence quality

45

Translational signal

35

Research bench value

38

Rationale GHRP-6 scores low on novelty and differentiation because it predates and is functionally inferior to later GHRPs on most axes; the cortisol/prolactin liability killed its clinical trajectory and ipamorelin has taken its place as the reference clean GHRP. The appetite/ghrelin angle is genuinely distinctive and gives it marginal bench value, but the evidence base is messy and the compound just isn’t a priority for any serious program in 2025.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Growth hormone releasing peptide / ghrelin receptor agonist

A first-generation hexapeptide ghrelin receptor agonist with prominent appetite stimulation, often used as a research-grade alternative to ipamorelin.

Abstract

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; CAS 87616-84-0; molecular formula C46H56N12O6; molecular weight 873.02) is a first-generation hexapeptide ghrelin receptor agonist. The compound stimulates GH release with kinetics similar to GHRP-2 but produces more pronounced cortisol and prolactin elevation, which has limited its clinical development. GHRP-6 also produces marked appetite stimulation through ghrelin pathway activation, an effect that distinguishes it from later GHRPs and that may be either useful (cachexia, sarcopenia adjunct) or unwanted (weight management contexts) depending on the application. Pharmacokinetics: plasma half-life 15 to 60 minutes; parenteral administration only. Research-grade doses are typically 100 to 300 micrograms subcutaneously per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-077Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Seletracetam

Plain-language summaryIntrigue 36 / 100

Seletracetam is a difluorovinyl racetam developed by UCB as a higher-potency successor to levetiracetam. It binds SV2A with greater affinity. Development was halted in favor of brivaracetam. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

31/100

A discontinued SV2A also-ran with narrow probe value and no active development path

Look, seletracetam is basically a pharmaceutical footnote. UCB developed it in parallel with brivaracetam, both targeting the same SV2A binding site that levetiracetam had already validated. The difluorovinyl substituent at the pyrrolidinone 4-position is genuinely clever chemistry, delivering roughly 10-fold higher SV2A affinity than levetiracetam in binding assays. But here’s the thing: that advantage didn’t translate into a clinical win. Phase 2 data in partial-onset seizures showed efficacy that was essentially comparable to brivaracetam, with a slightly less favorable safety read. UCB made the call in 2007 to advance brivaracetam, which is now an approved antiseizure agent with a real regulatory package behind it. Seletracetam went on the shelf.

The SV2A story itself has become mature. When levetiracetam launched in 1999 the mechanism was genuinely mysterious, which is part of what made the class interesting. By the time brivaracetam hit Phase 3 the mechanism was well-characterized: modulation of synaptic vesicle protein 2A, reduction in neurotransmitter exocytosis at high firing frequencies. That’s solid biology, but it’s no longer frontier biology. Seletracetam doesnt add a new dimension to the mechanism, it just sits at a different point on the affinity curve.

The differentiation problem is the real killer here. The compound’s most direct comparator, brivaracetam, is FDA-approved, commercially available in clinical quantities, and has a mountain of safety and PK data. For any lab doing SV2A pharmacology work, brivaracetam is the obvious tool. Seletracetam could be interesting for structure-activity relationship studies specifically around the difluorovinyl scaffold, or as a comparator in displacement assays, and we think that narrow use case is real. But its bench value tops out there.

What we don’t like: the evidence base is frozen at Phase 2. No multi-lab replication of human data, no Phase 3 package, and nothing published in the last decade that moves the needle. The preclinical literature is thin outside of UCB’s own publications. The program closure was commercial, not mechanistic, so we’re not penalizing seletracetam for a disproven mechanism. SV2A agonism clearly works. The problem is brivaracetam already demonstrates that, better and with more data behind it.

Honestly, if you’re studying SV2A pharmacology, seletracetam is a reasonable secondary probe to keep in the toolkit. The affinity advantage matters in some displacement paradigms, and the structural comparison with brivaracetam is instructive for SAR work. But it’s not a compound that drives a research program. It’s a supporting actor in someone else’s story, and that story ended with brivaracetam’s NDA approval in 2016.

Novelty

25

Mechanism promise

30

In-category differentiation

20

Evidence quality

40

Translational signal

45

Research bench value

35

Rationale Seletracetam scores low primarily on novelty and differentiation: it lost an internal head-to-head against brivaracetam in 2007 and the program has been frozen ever since, leaving it as a structural curiosity in a now-mature receptor class. Its Phase 2 clinical data and 10x SV2A affinity advantage over levetiracetam rescue it from the bottom, but barely.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Difluorovinyl pyrrolidinone (high-affinity SV2A ligand)

A second-generation UCB SV2A ligand discontinued after Phase 2 due to commercial considerations despite favorable efficacy.

Abstract

Seletracetam (UCB 44212; (2S)-2-[(4R)-4-(2,2-difluorovinyl)-2-oxopyrrolidin-1-yl]butanamide; CAS 357336-74-4; molecular formula C10H14F2N2O2; molecular weight 232.23) is a second-generation SV2A ligand developed at UCB Pharma in parallel with brivaracetam. The compound features a difluorovinyl substituent at the pyrrolidinone 4-position, producing approximately 10-fold higher SV2A affinity than levetiracetam. Phase 2 trials in partial-onset seizures showed efficacy comparable to brivaracetam, but UCB discontinued the program in 2007 in favor of brivaracetam, which had a slightly more favorable safety profile in the development program. The compound is not approved by any regulatory authority and has no continuing clinical development. It is sold as a research chemical for investigational use. Pharmacokinetics in Phase 2 showed plasma half-life of approximately 8 hours and oral bioavailability above 80 percent. The compound provides an interesting case study in pharmaceutical decision-making where two structurally similar compounds with similar efficacy profiles led to selection of one for marketing.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-036Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
F-Phenibut (Fluorophenibut)

Plain-language summaryIntrigue 42 / 100

F-Phenibut is the fluorinated cousin of phenibut. It activates GABA-B receptors more potently than phenibut and has comparable dependence risk. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

GABA-B agonist / fluoro-phenibut

A 4-fluoro-substituted phenibut analog with higher GABA-B affinity and lower dose requirement; sold as a research chemical with elevated dependence concerns.

Abstract

F-Phenibut (4-amino-3-(4-fluorophenyl)butanoic acid) is a fluorinated analog of phenibut with the addition of a para-fluoro substituent on the phenyl ring. The structural modification increases GABA-B receptor affinity and produces effective doses approximately 5- to 10-fold lower than phenibut. The compound is not approved in any jurisdiction and is sold as a research chemical. Mechanism parallels phenibut (GABA-B agonist) with the affinity increase. Dependence liability is at least as substantial as phenibut and may be greater on a dose-equivalent basis. Pharmacokinetics are not formally characterized in humans; rodent half-life is similar to phenibut. Research-grade vendor doses are typically 50 to 250 mg per administration. F-phenibut should be regarded as a higher-potency phenibut analog with all the dependence concerns of phenibut amplified by potency.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-069Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
IGF-1 DES

Plain-language summaryIntrigue 58 / 100

IGF-1 DES is a truncated form of IGF-1 missing the first three amino acids. The truncation reduces binding to IGF-binding proteins, producing a more potent local muscle effect. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

IGFBP-resistant IGF-1 fragment with real local potency advantage but thin human data and dated novelty

IGF-1 DES is the truncated cousin of native IGF-1: lose the first three residues (Gly-Pro-Glu) and you drop IGFBP binding substantially, which means the free fraction at target tissue goes up and local potency climbs roughly 10-fold over native IGF-1 in head-to-head in vitro models. That’s a real pharmacological distinction, and it’s why this form shows up specifically in muscle, bone, and neural tissue studies where local receptor activation is the question you’re actually asking.

What we like: the IGFBP angle is genuinely useful as a research probe. IGF binding proteins are a confounding layer in nearly every IGF-1 study, and DES lets you bypass that layer directly. If you’re interrogating IGF-1R signaling in tissue culture or local injection models, DES produces a cleaner readout than native IGF-1 without the IGFBP sink eating your signal. The receptor binding characteristics are documented across multiple lab groups, the functional potency difference is reproducible, and the mechanism is well-defined enough that you know what question you’re answering when you use it.

The problem is that this compound has been around since the late 1980s. The core biochemistry, characterized by Ballard and colleagues and expanded substantially by Sara and Hall in the early 1990s, is thoroughly mapped. The truncation strategy is elegant, but its a 35-year-old elegance. Compared to a mitochondrial-derived peptide or a novel triple incretin, DES sits firmly in the established-but-not-exciting column. Novelty here is historical, not current.

Versus IGF-1 LR3, the comparison is real and worth making: LR3 extends half-life to hours via the Arg3 modification, which suits systemic and sustained-release models. DES gives you a 20-30 minute half-life with higher peak local effect, which fits local-injection tissue models better. These are genuinely different tools for genuinely different questions, not just dose variants. That differentiation earns DES a niche. It doesn’t, however, make it dominant in the broader IGF research space where LR3 has the deeper translational literature.

What we dont love: human-specific data on the DES form is sparse. Most clinical IGF-1 work uses native IGF-1 or mecasermin. The case that DES specifically outperforms in a human research context is largely extrapolated from preclinical, and the short half-life doesn’t meaningfully reduce systemic exposure under repeated-dosing protocols. The same proliferative risk considerations that shadow native IGF-1 apply here in full.

Honestly, DES earns its place in an IGF toolkit as a mechanistic probe. It’s not a headline compound in 2026. Real pharmacological distinction, solid bench utility in local tissue models, but the novelty window on this one closed a generation ago.

Novelty

38

Mechanism promise

52

In-category differentiation

48

Evidence quality

42

Translational signal

38

Research bench value

58

Rationale IGF-1 DES is a well-characterized truncation with a genuine pharmacological distinction (IGFBP bypass, ~10x local potency) that earns real bench utility, but the core biochemistry was mapped in the late 1980s and human-specific DES evidence remains sparse relative to LR3 or native IGF-1. Scores reflect a solid but non-exciting tool compound with modest translational signal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Truncated IGF-1 analog

A truncated form of IGF-1 missing the first three residues, with reduced IGFBP binding and increased local potency.

Abstract

IGF-1 DES (DES(1-3) IGF-1) is a truncated analog of human IGF-1 missing the first three N-terminal residues (Gly-Pro-Glu). The truncation reduces binding to IGF binding proteins (IGFBPs) and increases the free fraction of the peptide at target tissues, producing approximately 10-fold higher local potency than native IGF-1 at equivalent doses. The compound is sold as a research chemical. Plasma half-life is shorter than IGF-1 LR3 (approximately 20 to 30 minutes for IGF-1 DES vs hours for LR3) due to the absence of the Arg3 modification, but the increased local activity provides higher peak effects per dose. Investigational doses range widely; safety considerations parallel IGF-1 LR3 (chronic IGF-1 elevation effects on cancer risk and acromegalic features).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-088Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Coenzyme Q10 (Ubiquinol)

Plain-language summaryIntrigue 60 / 100

Coenzyme Q10 (ubiquinol when reduced) is an essential mitochondrial cofactor that participates in the electron transport chain. Levels decline with age and with statin use. Used as a heart-failure supplement and for energy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous mitochondrial cofactor

An endogenous redox cofactor of the mitochondrial electron transport chain, declining with age and statin use, sold as a dietary supplement.

Abstract

Coenzyme Q10 (CoQ10, ubiquinone; CAS 303-98-0; molecular formula C59H90O4; molecular weight 863.34) is an endogenous redox cofactor essential for mitochondrial electron transport between Complex I/II and Complex III. The compound is synthesized from tyrosine and the mevalonate pathway; statin use reduces endogenous synthesis through HMG-CoA reductase inhibition (the same pathway used for cholesterol synthesis). Plasma and tissue CoQ10 decline with age. Supplementation has been studied for cardiovascular function (heart failure, hypertension), statin-associated muscle symptoms, and migraine prophylaxis. Bioavailability of the oxidized form (ubiquinone) is poor; the reduced form (ubiquinol) has 3- to 5-fold better bioavailability and is the preferred supplemental form for elderly subjects with reduced redox capacity. Doses are typically 100 to 400 mg per day of ubiquinol or higher of ubiquinone.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-120Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vasopressin (DDAVP)

Plain-language summaryIntrigue 60 / 100

Vasopressin (antidiuretic hormone) and the synthetic analog DDAVP (desmopressin) regulate water retention by the kidneys. Used clinically for diabetes insipidus and bedwetting. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Well-understood approved neuropeptide with solid clinical data but limited frontier research appeal

Look, vasopressin is one of those compounds where the clinical story is genuinely impressive and the research-frontier story is… not. It’s been known as antidiuretic hormone since the 1950s, the V1a/V1b/V2 receptor pharmacology is textbook-level established, and DDAVP has been FDA-approved for central diabetes insipidus since the late 1970s. The approved indications work, the mechanism is understood, and the hemostatic use in hemophilia A and von Willebrand disease type 1 represents real clinical value. None of that translates into a compelling research target for 2025.

The mechanism isnt bad on paper. V1b agonism in pituitary corticotrophs puts AVP squarely in the HPA axis conversation alongside CRH, and theres genuine academic interest in how the AVP/CRH synergy regulates ACTH release under stress. The social neuroscience angle, made famous by prairie vole studies on V1aR and pair bonding, spawned a decade of intranasal paradigms looking at trust, social memory, and aggression. We think that literature is interesting but also somewhat exhausted. The human signal for vasopressin’s social and cognitive effects has been inconsistent, and the intranasal delivery route introduces confounds that have complicated interpretation for years.

What we do like: DDAVP’s selectivity for V2 over V1 receptors makes it a reasonably clean probe for aquaporin-2 trafficking and collecting duct water transport physiology. If your lab is doing renal tubular biology or studying aquaporin regulation, DDAVP earns its place on the shelf. For V1b work on stress axis biology, native AVP is more appropriate than the synthetic analog. Those are real and defensible bench applications, just not frontier ones.

The cognitive enhancement use case, historically delivered at 1 to 2 IU intranasally, has a thin and unreplicated evidence base. The early Weingartner studies from the 1980s were never robustly confirmed. This isnt a developing story; it’s a closed one. The signal didnt survive scrutiny, and the more tractable approaches to neuropeptide-based cognition research have moved elsewhere.

Honestly, vasopressin scores where it scores because the compound is genuinely useful pharmacology in its approved lane and has bench probe value in specific subfields, but there’s no frontier angle that would make a serious investigator prioritize it over newer targets. High evidence quality and translational confidence for what it does; low novelty and differentiation for what it doesnt. That’s the tension that lands it here.

Novelty

22

Mechanism promise

33

In-category differentiation

35

Evidence quality

75

Translational signal

70

Research bench value

50

Rationale Vasopressin is a decades-old endogenous hormone with FDA-approved indications and a thoroughly mapped receptor pharmacology; its evidence quality and translational signal are high for approved uses, but novelty is low and the cognitive-enhancement research angle that made it culturally interesting in nootropic circles has largely failed to produce meaningful human signal, dragging differentiation and mechanism promise toward the middle of the scale.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous nonapeptide hormone

An endogenous nonapeptide hormone for water retention and vasoconstriction; the synthetic analog desmopressin (DDAVP) is FDA-approved for diabetes insipidus.

Abstract

Vasopressin (arginine vasopressin, AVP, antidiuretic hormone; CAS 113-79-1; molecular weight 1084.23) is an endogenous nonapeptide synthesized in the paraventricular and supraoptic nuclei. The synthetic analog desmopressin (DDAVP; deamino-D-arginine vasopressin) is FDA-approved for diabetes insipidus, primary nocturnal enuresis, hemophilia A, and von Willebrand disease type 1. Mechanism includes V1a (vascular smooth muscle), V1b (pituitary corticotrophs), and V2 (renal collecting duct) receptor agonism. Cognitive enhancement applications historically used intranasal vasopressin (1 to 2 IU intranasally) but the evidence base is weak and current clinical use is largely limited to the approved water-balance and hemostatic indications.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-136Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Doxepin (Low-Dose)

Plain-language summaryIntrigue 60 / 100

Doxepin is an old tricyclic antidepressant. At very low doses (3-6 mg, sold as Silenor) it works as an H1 antihistamine sleep aid without the antidepressant or anticholinergic effects of full doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

A 1969 TCA repurposed as a sleep drug; solid approval story, minimal research frontier appeal

Look, doxepin is a 1969 tricyclic antidepressant. The fact that someone noticed, decades later, that its H1 antagonism dominates at 3 to 6 mg and reformulated it as Silenor in 2010 is genuinely clever pharmacology. But clever is not the same as novel, and that distinction matters a lot for how we score this.

The mechanism insight here is dose-dependent receptor selectivity: at antidepressant doses (75 to 300 mg), doxepin hits muscarinic, alpha-1 adrenergic, and serotonergic receptors in ways that produce the classic TCA side-effect burden. Drop to the 3 to 6 mg range and what you’re left with is fairly selective H1 antagonism. That H1 blockade produces sleep continuity effects, meaning it targets maintenance insomnia, the 3am-wakeup phenotype, rather than onset. Thats a real and underappreciated clinical distinction. The plasma half-life of 15 hours is actually what makes it work; the drug is still present when early-morning sleep tends to fragment.

Here’s the thing, though: this story is 15 years old now. The Silenor approval trials (Krystal et al., Scharf et al., the 2010 package of phase 3 data) are well-replicated and well-designed. The evidence is solid. But the research conversation around sleep maintenance has largely moved on to orexin receptor antagonists. Suvorexant and lemborexant target the same clinical phenotype through a mechanism that most sleep researchers find considerably more interesting, and the dual-orexin-receptor angle has generated far more bench-level investigation over the last decade.

As a research probe, doxepin low-dose doesnt offer much that you couldnt get from a more selective H1 antagonist if H1 biology is what you’re actually studying. The 15-hour half-life makes washout kinetics awkward. Its not scheduled, which is a minor sourcing convenience relative to z-drugs or benzodiazepines, but that attribute alone doesnt make it an interesting bench target.

We think the honest placement here is: doxepin low-dose has good clinical evidence and a real approved indication, and it works. But “works for its indication” and “worth a serious investigator’s time in 2025” are different questions. The H1-for-sleep-maintenance story is mature and well-understood. The mechanism isnt revealing new biology. The differentiation from orexin antagonists cuts against it, not for it. If you’re building a sleep research program, this compound answers questions you mostly already know the answer to.

Novelty

22

Mechanism promise

25

In-category differentiation

38

Evidence quality

70

Translational signal

68

Research bench value

28

Rationale Doxepin low-dose scores as established-mature because the clinical evidence is real and replicated (FDA approval, multiple phase 3 RCTs for Silenor), but the mechanism is H1 antagonism, the literature is 15 years old on the low-dose reformulation angle, and orexin antagonists have largely superseded it as the more mechanistically interesting sleep-maintenance target. Low bench value as a probe compound drags the overall further.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant / H1 antagonist

A tricyclic antidepressant FDA-approved at low doses (3 to 6 mg) as Silenor for sleep maintenance insomnia, exploiting selective H1 antihistamine activity at the low end of the dose range.

Abstract

Doxepin (Silenor at low doses; CAS 1668-19-5) is a tricyclic antidepressant approved at antidepressant doses (75 to 300 mg) since 1969 and reformulated at low doses (3 to 6 mg) by Somaxon and approved as Silenor in 2010 for sleep maintenance insomnia. At low doses, the compound shows selective H1 antihistamine activity; muscarinic, alpha-1 adrenergic, and serotonergic activities relevant at higher antidepressant doses are minimal. The H1-mediated sleep maintenance effect targets sleep continuity rather than sleep onset. Pharmacokinetics: plasma half-life 15 hours; CYP2D6 and CYP1A2 metabolism. Schedule status: prescription-only; not federally scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-152Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Magnesium Glycinate

Plain-language summaryIntrigue 50 / 100

Magnesium glycinate (also called magnesium bisglycinate) is magnesium bound to two glycine molecules. Glycine is also a calming amino acid, and the combination is well tolerated and absorbed without GI side effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic mineral

23/100

A well-absorbed magnesium chelate that handles repletion well but offers no genuine research frontier

Look, magnesium glycinate is a better mousetrap for magnesium delivery, not a research frontier. The chelation with glycine solves a real problem: magnesium oxide, the dominant commercial form, has notoriously poor absorption (roughly 4-12% in clinical studies versus approximately 80% for the bisglycinate chelate), which means most people supplementing with oxide are largely supplementing with expensive stools. Glycinate fixes that. That’s genuinely useful, but it’s been understood for decades and doesn’t open a new research question.

The glycine component does add something worth noting. Glycine acts as a co-agonist at the NMDA receptor glycine site, and at doses needed to deliver 200-400 mg elemental magnesium you’re getting roughly 1-2 g glycine per serving, which overlaps with the sleep-promotion literature (Bannai et al., 2012, Frontiers in Neurology). The combination is biologically sensible. But “biologically sensible” isn’t “novel research territory.” Both components are well-characterized independently, and theres no unique pharmacological fingerprint to the chelate that you couldn’t dissect by studying magnesium and glycine separately in a cleaner design.

As a bench tool, magnesium glycinate is weak. Investigators studying NMDA glycine site pharmacology have far more specific probes. Investigators studying magnesium in the CNS would reach for L-threonate, which carries the documented CSF-targeting story out of the Slutsky lab at MIT and a genuinely differentiated mechanistic rationale. The bisglycinate form doesn’t give you precision or resolution you can’t get another way, and the literature treating it as a distinct research compound rather than a delivery vehicle is thin at best.

The differentiation story falls short too. It clearly beats oxide on GI tolerability and elemental yield. But magnesium taurate, malate, and L-threonate are credible comparators for different indications, and glycinate doesn’t dominate the class on any dimension beyond tolerability. That’s useful for compliance studies and population-level repletion trials. It’s not interesting for basic science.

What we’d say plainly: the evidence quality here is reasonable because the underlying magnesium and glycine literatures are large and mature. That’s not a point in favor of glycinate as a research target; it’s evidence the interesting questions in this space have mostly been answered. Repletion in deficient populations? Well-characterized. Novel mechanism, unexplored indication space, surprising biology? Absent. The score reflects a compound that does exactly what it promises, has been doing it for decades, and wont generate findings a bench scientist is going to find worth writing up.

Novelty

16

Mechanism promise

22

In-category differentiation

28

Evidence quality

32

Translational signal

22

Research bench value

15

Rationale Magnesium glycinate improves on oxide meaningfully via bioavailability and adds mild glycine pharmacology at the NMDA co-agonist site, but neither angle constitutes novel research territory; both components are fully characterized independently, there is no unique mechanistic fingerprint to the chelate, and the calculated score of 23 lands well below the generic-mineral ceiling without needing the cap to bind.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Magnesium-glycine chelate

A magnesium chelate with glycine, with superior bioavailability and minimal gastrointestinal effects compared with magnesium oxide.

Abstract

Magnesium glycinate (magnesium bisglycinate) is a chelated magnesium salt where magnesium is bound to two molecules of glycine. The compound has superior bioavailability compared with magnesium oxide (the most common but poorly absorbed form), with absorption rates approaching 80 percent in clinical studies versus 4 to 12 percent for oxide. Glycine has independent anxiolytic and sleep-promoting effects through NMDA glycine site activity. The combination produces a magnesium product with low gastrointestinal disturbance and additional glycine benefits at the dosing required for elemental magnesium repletion. Doses providing 200 to 400 mg elemental magnesium per day are typical.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-168Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
SAM-e (S-Adenosyl-L-Methionine)

Plain-language summaryIntrigue 65 / 100

SAM-e is the body’s principal methyl donor, used in countless biological reactions including neurotransmitter synthesis. As a supplement it has antidepressant effects with reasonable evidence and is used for liver disease and osteoarthritis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

37/100

Decades-old methyl donor with real but modest clinical evidence, largely mined-out research territory

SAM-e has been a fixture in the depression and liver-disease literature since Italian investigators began publishing on it in the 1970s. Fifty years of literature is the first signal: this isn’t a discovery, it’s established biochemistry. The mechanism is real. SAM-e is the universal methyl donor, participating in over 100 cellular transmethylation reactions including DNA methylation, neurotransmitter precursor steps, and phosphatidylcholine synthesis via the PEMT pathway. What we like is that this actually matters biologically. What we dont like is that “biologically important” and “interesting current research target” arent the same thing.

The clinical story is genuinely better than most compounds in this library. Several European regulatory agencies approved SAM-e as a prescription medicine for depression and osteoarthritis, and that’s translational signal most research compounds will never achieve. Meta-analyses, including the Papakostas group’s work and the AHRQ systematic review, report antidepressant effect sizes broadly comparable to SSRIs in small-N comparisons (SMD roughly 0.3 to 0.5). The OA data is similarly positive at modest scale. There’s also a hepatoprotective literature, particularly for alcohol-associated liver disease and NAFLD, where methionine cycle disruption is mechanistically coherent and the evidence is credible.

Here’s the problem: none of this is generating new questions. The depression literature effectively peaked in the late 1990s and early 2000s. Researchers cite those trials in background sections now, not as frontiers to build on. The mechanism is too diffuse to work as a specific probe; methylating everything across a hundred pathways isn’t the same as answering a targeted biological question. If you want to perturb DNA methylation specifically, DNMT inhibitors like 5-azacytidine or decitabine give precision that SAM-e can’t. If you’re working on one-carbon metabolism, SAM-e tends to be an output you measure, not the primary intervention you deploy.

The most live contemporary angle is in liver disease and, to a lesser extent, the aging/epigenetics interface. Groups studying MAT1A to MAT2A synthetase isoform switching in ALD and NAFLD, including work from Mato and colleagues at CIC bioGUNE on hepatic methionine cycle dysregulation, are doing genuinely interesting things with SAM-e as a metabolic variable. Thats the narrowest slice where we’d still look for new signal. But it’s a contracting frontier, not an expanding one.

Honestly, SAM-e scores like what it is: an endogenous metabolite with fifty years of evidence, a mechanism that’s well-understood and diffuse, and no category where it’s clearly best-in-class today. The clinical evidence is better than many compounds at this score level, which keeps it from the floor, but there’s little here to build a new program around. Solid reference material for background reading, not a primary target.

Novelty

18

Mechanism promise

30

In-category differentiation

35

Evidence quality

52

Translational signal

58

Research bench value

38

Rationale SAM-e is foundational endogenous biochemistry with a genuine multi-decade clinical literature in depression and liver disease, but the mechanism is too diffuse to serve as a specific research probe, the literature peaked in the early 2000s, and there is no category where it is clearly best-in-class today; the raw calculation lands just under the foundational-metabolite structural ceiling.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous methyl donor

S-adenosyl-L-methionine, the principal methyl donor for cellular methylation reactions, supplemented for depression, osteoarthritis, and liver disease.

Abstract

SAM-e (S-adenosyl-L-methionine; CAS 29908-03-0; molecular formula C15H22N6O5S; molecular weight 398.44) is an endogenous nucleotide-amino acid conjugate that serves as the principal methyl donor for hundreds of cellular methylation reactions, including DNA methylation, neurotransmitter synthesis, phospholipid synthesis, and detoxification. Synthesis from methionine + ATP is rate-limited; supplementation provides methyl donor capacity. The compound is approved as a medicine in some European countries for depression and osteoarthritis; sold as a dietary supplement in the United States. Clinical evidence in depression is moderate (effect sizes comparable to standard antidepressants in small trials). Doses are typically 400 to 1600 mg per day in divided administrations. Can precipitate mania in bipolar patients; should not be combined with MAOIs.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-185Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 42 43 44 45 46 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.